RansiMSomaratneMDFACC

PubMed

• 407 citations
  Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER...
  Robert P. Giugliano, Terje R. Pedersen, Jeong Gun Park, Gaetano M. De Ferrari, Zbigniew Gaciong
  Lancet. 2017-10-28
• 518 citations
  PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2) : a randomised, double-blind, placebo-controlled trial
  Frederick J. Raal, Evan A. Stein, Robert Dufour, Traci Turner, Fernando Civeira
  Lancet. 2015-01-24
• 747 citations
  Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial
  Stephen J. Nicholls, Rishi Puri, Todd J. Anderson, Christie M. Ballantyne, Leslie Cho
  JAMA. 2016-12-13

Journal Articles

• Original Investigation Effect of Evolocumab on Coronary Plaque Composition  
  Steven E Nissen, Ransi Somaratne, Rishi Puri, Christie M Ballantyne, ScienceDirect
• Rationale and Design of a Randomized Study to Assess the Efficacy and Safety of Evolocumab in Patients with Diabetes and Dyslipidemia: The BERSON Clinical Trial  
  Ransi Somaratne, Jonathan Fialkow, Clinical Cardiology
• Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency  
  Anker SD, Schroeder S, Atar D, Bax JJ, Ceconi C, Cowie MR, Crisp A, Dominjon F, Ford I, Ghofrani HA, Gropper S, Hindricks G, Hlatky MA, Holcomb R, Honarpour N, Jukema ..., Eur J Heart Failure, 1/1/2016
• Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data  
  Sattar N, Preiss D, Robinson JG, Djedjos CS, Elliott M, Somaratne R, Wasserman SM, Raal F, Lancet Diabetes and Endocrinol., 1/1/2016
• PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role  
  Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Seidah NG, Honarpour N, Lira A, Xue A, Chiruvolu P, Jackson S, Di M, Peach M, Somaratne R, Wasserman SM, Scott R,..., J Lipid Res, 1/1/2016
• Impact of PCSK9 Inhibition on Coronary Atheroma Progression: Rationale and Design of GLAGOV (Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured b...  
  Puri R, Nissen SE, Somaratne R, Cho L, Kastelein JJP, Ballantyne CM, Koenig W, Anderson TJ, Yang J, Kassahun H, Wasserman SM, Scott R, Borgman M, Nicholls SJ, American Heart Journal, 1/1/2016
• Evolocumab lowers LDL-C safely and effectively when selfadministered in the at-home setting  
  Dent-Acosta R, Joshi R, Djedjos S, Legg J, Elliott M, Geller M, Meyer, D, Somaratne R, Recknor C, Weiss R, Springerplus, 1/1/2016
• Impact of Target-mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)  
  J Clinical Pharmacol., 1/1/2016
• PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial  
  Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I..., The Lancet, 1/1/2015
• Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled anal...  
  Stein EA, Giugliano RP, Koren MJ, Raal FJ, Roth EM, Weiss R, Sullivan D, Wasserman SM, Somaratne R, Kim JB, Yang J, Liu T, Albizem M, Scott R, Sabatine MS; PROFICIO In..., Eur Heart J, 1/1/2014
• Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholest...  
  Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanvelu S, Hoffman E, McDonald S, Abrahamsen T, Wasserman S, Scott R, Sabatine M, for the LA..., The Lancet, 1/1/2012
• Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients Wit...  
  Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA., Circulation, 1/1/2012
• CardioCheck: A Biomarker Assay Program Designed for Cardiotoxicity Testing in Early Phase Pre-clinical Drug Development  
  Shell SA, Wappel R, Turner JR, Somaratne R, Bacus SS, Quintiles White Paper, 1/1/2011
• Pharmaceutical Interventions for Obesity: A Public Health Perspective  
  Caveney E, Caveney BJ, Somaratne R, Turner JR, Gougiotis L., Diabetes, Obesity and Metabolism, 1/1/2011
• Centralised Endpoint Adjudication in Cardiovascular Outcomes Studies: Composite Endpoints, Risk Ratios and Clinical Endpoints Committees  
  Tyner CA, Somaratne R, Cabell CH, Turner JR., Journal of Clinical Studies, 1/1/2011
• Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events  
  Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA for the OSLER Invest..., New England Journal of Medicine, 1/15/2015
• AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein chole...  
  Desai NR, Giugliano RP, Zhou J, Kohli P, Somaratne R, Hoffman E, Liu T, Scott R, Wasserman SM, Sabatine MS, J Am Coll Cardiol., 1/11/2014
• Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term...  
  Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, Liu T, Scott R, Wasserman SM, Sabatine MS; OSLER Investigators., Circulation, 1/14/2014
• AMG 145, A Monoclonal Antibody Against PCSK9, Significantly Reduces Lipoprotein (a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LAP...  
  Desai NR, Kohli P, Giugliano RP, O’Donoghue M, Somaratne R, Zhou J, Hoffman E, Huang F, Rogers WJ, Wasserman SM, Scott R, Sabatine MS., Circulation, 1/24/2013
• Join now to see all

Abstracts/Posters

• Impact of Evolocumab Therapy in Patients with Discordance Between LDL-C and LDL-P.
  Toth PP, Sattar N, Blom D, Martin S, Jones S, Monsalvo ML, Elliott M, Somaratne R, Preiss D, American College of Cardiology Scientific Sessions, Washington DC, 1/1/2017
• Effect of Evolocumab on Low Density Lipoprotein Particles.
  Toth PP, Banach M, Yang X, Elliott M, Davis M, Somaratne R, Martin SM, Jones SR, American College of Cardiology Scientific Sessions, Chicago, 1/1/2016
• Effect of Evolocumab on Remnant Lipoprotein Particles.
  Toth PP, Jones SR, Yang X, Elliott M, Davis M, Somaratne R, Martin SM, Banach M, American College of Cardiology Scientific Sessions, Chicago, 1/1/2016
• Impact of Body Weight on Dosing Regimen of Evolocumab for Hypercholesterolemia
  Mahlof E, Koren MJ, Emery M, Doshi S, Liu T, Somaratne R, Wasserman SM, Sperling L, European Society of Cardiology Congress, London, UK, 1/1/2015
• The Diagnosis of Heterozygous Familial Hypercholesterolemia: Genotype versus Phenotype
  Raal F, Stein EA, Cariou B, Gaudet D, Genest J, Somaratne R, Bridges I, Wasserman S, Scott R, Hovingh GK., American Heart Association Scientific Sessions, Chicago, 1/1/2014
• Safety and Tolerability of Very Low LDL-C Levels in Patients Treated with 52 Weeks of Evolocumab (AMG 145).
  Koren MJ, Blom D, Giugliano RP, Stroes E, Somaratne R, Lowy A, Monsalvo ML, Hsu H, Wasserman S, Scott R, Sabatine MS, American Heart Association Scientific Sessions, Chicago, 1/1/2014
• Safety, Tolerability, and Efficacy of Longer-term Administration of AMG 145: Interim Results From the OSLER Study
  Koren MJ, Giugliano RP, Raal F, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, Xu F, Sabatine MS, European Society of Cardiology, Amsterdam, NL, 9/2/2013
• Statin Therapy is a Major Determinant of PCSK9 Plasma Concentration: Data from Four Clinical Trials with AMG 145
  Civeira F, Raal F, Stein EA, Schou MB, Basart DCG, Koren MJ, Ceska R, Somaratne R, Yang, Sabatine MS, European Society of Cardiology, Amsterdam, NL, 8/31/2013
• Safety of AMG 145, a Fully Human Monoclonal Antibody to PCSK9: Data from Four Phase 2 Studies in 1314 Patients
  Giugliano RP, Raal FJ, Koren MJ, Sullivan D, Roth EM, Weiss R, Somaratne R, Yang J, Sabatine MS, Stein EA, European Society of Cardiology, Amsterdam, NL, 8/31/2013
• Statin therapy is a major determinant of plasma PCSK9 concentration: data from four clinical trials with AMG 145.
  Civeira F, Raal, F, Stein EA, Schou MB, Basart DC, Koren MJ, Somaratne R, Yang J, Sabatine MS, European Society of Cardiology Congress, Amsterdam, The Netherlands, 1/1/2013
• Safety of AMG 145, a fully human monoclonal antibody to PCSK9: data from 4 phase 2 studies in 1314 patients.
  Giugliano RP, Raal F, Koren MJ, Sullivan D, Roth EM, Weiss R, Somaratne R, Yang, J, Sabatine MS, Stein EA., European Society of Cardiology Congress, Amsterdam, The Netherlands, 1/1/2013
• Safety, tolerability and efficacy of long-term administration of AMG 145: preliminary results from the OSLER study.
  Koren MJ, Giugliano RP, Raal F, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, Xu F, Sabatine MS, European Society of Cardiology Congress, Amsterdam, The Netherlands, 1/1/2013
• Reduction in Lipoprotein (a) with the PCSK9 Inhibitor AMG145 in Hypercholesterolemic Patients on Background Statin: Results from the LAPLACE-TIMI 57 Trial
  Kohli P, Desai N, Giugliano RP, O'Donoghue ML, Somaratne R, Hoffman EB, Huang F, Wasserman SM, Scott R, Sabatine MS, American Heart Association Scientific Sessions, Los Angeles, CA, 1/1/2012
• Join now to see all